GCSB 5

Drug Profile

GCSB 5

Alternative Names: GCSB; GCSB-5; Shinbaro

Latest Information Update: 26 Aug 2013

Price : $50

At a glance

  • Originator Green Cross
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Herbal medicines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 26 Jul 2013 Seoul National University Hospital & Green Cross plan a phase II/III trial for Osteoarthritis in South Korea (NCT01910116)
  • 01 Sep 2011 Launched for Osteoarthritis in South Korea (PO)
  • 24 Aug 2011 Green Cross & LG Life Sciences agree to co-promote GCSB 5 in South Korea for Osteoarthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top